Imagine a vaccine that works like a high-resolution photo of a virus's 'key' to enter cells, teaching the body to block it. Instead of using a live virus, it uses a lab-made protein piece that is safer and easier to handle. It's designed to be a booster that can be quickly updated whenever the virus changes its look.
Existing COVID-19 vaccines often exclude high-risk groups like immunocompromised adults and children from Phase III trials. There is also a need for a flexible vaccine platform that can be quickly updated for new variants without starting from scratch.
A recombinant protein vaccine (BIMERVAX®) based on an RBD fusion heterodimer and an adaptable manufacturing platform for variant-specific doses.
If you are a vaccine manufacturer dealing with the need for non-mRNA alternatives — this project developed a recombinant protein platform that allows for the creation of vaccines against Alpha and Beta variants. This provides a diversified product pipeline for different patient needs.
If you are a clinic dealing with patients who cannot take standard vaccines — this project tested the BIMERVAX® vaccine on 350 children and 240 immunosuppressed adults. This offers a validated safety profile for high-risk groups.
If you are a CDMO dealing with the demand for scalable protein-based therapies — this project enhanced manufacturing capabilities for recombinant RBD fusion heterodimers. This demonstrates a viable path for large-scale European production.
Based on available project data, there is no information regarding the specific cost or pricing of the vaccine.
Yes, the project involved 11 industry partners and specifically mentioned that manufacturing capabilities were enhanced during the second reporting period.
Based on available project data, the vaccine is developed by HIPRA and referred to as BIMERVAX®, but specific licensing terms are not provided.
The platform is adaptable and was used to develop formulations for emerging variants, including Alpha and Beta strains.
The project aims to manufacture and test the first recombinant protein-based vaccine to be authorized in Europe.
The consortium is heavily industry-weighted with 11 companies (55% ratio), including 3 SMEs, which suggests a strong drive toward commercialization. With 20 partners across 6 countries (DE, ES, IT, TR, UK, US), the project leverages a broad international network of 7 research entities and 2 other organizations to bridge the gap between lab research and market entry.
Contact HIPRA SCIENTIFIC SL in Spain
Contact us to explore licensing opportunities for the BIMERVAX® protein platform.
